Immune Design (IMDZ) Reports Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
Tweet Send to a Friend
Immune Design (NASDAQ: IMDZ) today announced the launch of the patient and healthcare provider websites for the SYNOVATE study – ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
